Month: November 2018

Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

old WP ej via Cision / By

GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of Roger Tell, MD., PhD as Chief Scientific Officer (CSO) and Senior Vice President (SVP) of clinical development. Dr. Tell has more than a decade of experience as a clinical oncologist in addition to holding management …

Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development Read More »

Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

Nyhetsbrev

GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of Roger Tell, MD., PhD as Chief Scientific Officer (CSO) and Senior Vice President (SVP) of clinical development. Dr. Tell has more than a decade of experience as a clinical oncologist in addition to holding management and advisory positions at Eli Lilly, AstraZeneca, Merck, Servier and Aprea Therapeutics. As the new chief scientific officer, Dr. Tell will be in charge of scientific research and technical operations at Isofol. Dr. Tell will also be involved in the strategy and developing of the clinical program for Isofol’s leading product candidate, arfolitixorin, now entering a global pivotal phase 3 clinical study.

Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

News / By

GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of Robert Marchesani as an advisor to its board of directors. Mr. Marchesani has nearly 30 years of experience in the life science industry, leading a variety of business activities including product development, global branding and …

Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors Read More »

Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

Nyhetsbrev

GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of Robert Marchesani as an advisor to its board of directors. Mr. Marchesani has nearly 30 years of experience in the life science industry, leading a variety of business activities including product development, global branding and marketing with a particular focus on oncology.

Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

old WP ej via Cision / By

GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the pivotal Phase 3 clinical trial, the ISO-CC-007 study, for the treatment of first-line (initial) metastatic colorectal cancer (mCRC). Anders Rabbe, chief executive officer of Isofol, said, “We look forward to bringing arfolitixorin to all patients …

Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer Read More »

Scroll to Top